Artículos por temáticas

Accuracy and Reliability of Onset Detection Algorithms in Gait Initiation for Healthy Controls and Participants With Parkinson's Disease.

Chen A, Selvaraj S, Krishnan V, Asgari S.

J Appl Biomech. 2019 Oct 18:1-8. doi: 10.1123/jab.2018-0431. [Epub ahead of print]

Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson's Disease

Fine JM, Stroebel BM, Faltesek KA, Terai K, Haase L, Knutzen KE, Kosyakovsky J, Bowe TJ, Fuller AK, Frey WH, Hanson LR.

Neurosci Lett. 2020 Jan 1;714:134567. doi: 10.1016/j.neulet.2019.134567. Epub 2019 Oct 16.

Evolution of impulsive-compulsive behaviors and cognition in Parkinson's disease

Erga AH, Alves G, Tysnes OB, Pedersen KF.

J Neurol. 2020 Jan;267(1):259-266. doi: 10.1007/s00415-019-09584-7. Epub 2019 Oct 18.

Glycolysis as a therapeutic target for Parkinson's disease.

Foltynie T.

Lancet Neurol. 2019 Oct 15. pii: S1474-4422(19)30404-1. doi: 10.1016/S1474-4422(19)30404-1. [Epub ahead of print] No abstract available.

Direct cost of Parkinson's disease in a health system with high judicialization: evidence from Colombia

Prada SI, Pérez AM, Valderrama-Chaparro J, Molina-Echeverry MI, Orozco JL, Takeuchi Y.

Expert Rev Pharmacoecon Outcomes Res. 2020 Dec;20(6):587-593. doi: 10.1080/14737167.2020.1681266. Epub 2019 Oct 18.

Association of Wolff-Parkinson-White with Left Ventricular Noncompaction Cardiomyopathy in Children.

Howard TS, Valdes SO, Hope KD, Morris SA, Landstrom AP, Schneider AE, Miyake CY, Denfield SW, Pignatelli RH, Wang Y, Kim JJ.

J Card Fail. 2019 Oct 15. pii: S1071-9164(19)30051-X. doi: 10.1016/j.cardfail.2019.09.014. [Epub ahead of print]

Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease

Mishra A, Singh S, Tiwari V, Bano S, Shukla S.

Behav Brain Res. 2020 Jan 27;378:112304. doi: 10.1016/j.bbr.2019.112304. Epub 2019 Oct 15.

Development of a Joint Commission Disease-Specific Care Certification Program for Parkinson Disease in an Acute Care Hospital.

Azmi H, Cocoziello L, Harvey R, McGee M, Desai N, Thomas J, Jacob B, Rocco A, Keating K, Thomas FP.

J Neurosci Nurs. 2019 Oct 15. doi: 10.1097/JNN.0000000000000472. [Epub ahead of print]

Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations

Ando K, Inoue T, Hikishima K, Komaki Y, Kawai K, Inoue R, Nishime C, Nishinaka E, Urano K, Okano H.

Behav Pharmacol. 2020 Feb;31(1):45-60. doi: 10.1097/FBP.0000000000000509.

[Parkinson's Disease: Clinical Review and Update].

Cabreira V, Massano J.

Acta Med Port. 2019 Oct 1;32(10):661-670. doi: 10.20344/amp.11978. Review. Portuguese.

Plant Polyphenols as Neuroprotective Agents in Parkinson's Disease Targeting Oxidative Stress

Hor SL, Teoh SL, Lim WL.

Curr Drug Targets. 2020;21(5):458-476. doi: 10.2174/1389450120666191017120505.

Does restless legs syndrome impact cognitive function via sleep quality in adults with Parkinson's disease?

Cederberg KL, Brinkley EB, Belotserkovkaya N, Memon RA, Motl RW, Amara AW.

Int J Neurosci. 2020 Apr;130(4):322-329. doi: 10.1080/00207454.2019.1681423. Epub 2019 Oct 25.

Advantages of using 3D virtual reality based training in persons with Parkinson's disease: a parallel study.

Cikajlo I, Peterlin Potisk K.

J Neuroeng Rehabil. 2019 Oct 17;16(1):119. doi: 10.1186/s12984-019-0601-1.

Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease.

Lin CH, Liu HC, Yang SY, Yang KC, Wu CC, Chiu MJ.

J Clin Med. 2019 Oct 3;8(10). pii: E1601. doi: 10.3390/jcm8101601.

Drug Choices and Advancements for Managing Depression in Parkinson's Disease

Assogna F, Pellicano C, Savini C, Macchiusi L, Pellicano GR, Alborghetti M, Caltagirone C, Spalletta G, Pontieri FE.

Curr Neuropharmacol. 2020;18(4):277-287. doi: 10.2174/1570159X17666191016094857.